Neuro-Biotech Corp. (MRES.PK) Performs Reverse Split and Name Change to The Institute of Biomedical Research Corp.
25 Aprile 2014 - 8:45PM
Marketwired
Neuro-Biotech Corp. (MRES.PK) Performs Reverse Split and Name
Change to The Institute of Biomedical Research Corp.
PODGORICA, MONTENEGRO--(Marketwired - Apr 25, 2014) -
Neuro-Biotech Corp. (OTC Pink: MRES) (PINKSHEETS: MRES) announced
today that Effective Monday, April 28, 2014, there will be a
reverse split of 10-1 on MRES stock. Also effective Monday, the
corporate name of Neuro-Biotech Corp. will be changed to: The
Institute of Biomedical Research Corp.
The Institute of Biomedical Research is an ambitious biomedical
business venture whose activities extend from highly diversified
scientific research and sophisticated services research and
development, quality control and standardisation of
pharmaceuticals, (cosmetics and food products) up to major long
term biomedical and environmental research projects, as well as the
development of new diagnostic technologies and innovative
experimental medical treatments. Regulatory certification of new
drugs and biomedical products also constitutes important business
activities of the Institute. The Institute is essential for the
development of Montenegro within the regional and European
environment.
Dr. Drasko Pekovic, President of MRES, said, "These changes will
enable the Institute to increase its international
recognition and prosperous future, This is a large step
forward in the further development of the Institute, and increased
shareholder value. We are confident that these changes will have a
positive effect moving forward. Our facilities are fully prepared
to continue and expand their services throughout the European Union
and beyond."
Legal Notice Regarding Forward-Looking Statements No statement
herein should be considered an offer or a solicitation of an offer
for the purchase or sale of any securities. This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although Neuro-Biotech Corp. (the "Company" or "MRES") believes
that the expectations reflected in the forward-looking statements
and the assumptions upon which they are based are reasonable, it
can give no assurance that such expectations and assumptions will
prove to have been correct. Forward-looking statements, which
involve assumptions and describe our future plans, strategies, and
expectations, are generally identifiable by use of the words "may,"
"will," "should," "could," "expect," "anticipate," "estimate,"
"believe," "intend," or "project" or the negative of these words or
other variations on these words or comparable terminology. The
reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous factors and uncertainties, including but not limited to
adverse economic conditions, intense competition, lack of
meaningful research results, entry of new competitors and products,
adverse federal, state and local government regulation, inadequate
capital, unexpected costs and operating deficits, increases in
general and administrative costs, termination of contracts or
agreements, technological obsolescence of the Company's products,
technical problems with the Company's research and products, price
increases for supplies and components, litigation and
administrative proceedings involving the Company, the possible
acquisition of new businesses or technologies that result in
operating losses or that do not perform as anticipated,
unanticipated losses, the possible fluctuation and volatility of
the Company's operating results, financial condition and stock
price, losses incurred in litigating and settling cases, dilution
in the Company's ownership of its business, adverse publicity and
news coverage, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and
research scientists, changes in interest rates, inflationary
factors, and other specific risks. There can be no assurance that
further research and development will validate and support the
results of our preliminary research and studies. Further, there can
be no assurance that the necessary regulatory approvals will be
obtained or that Ceres Ventures will be able to develop
commercially viable products on the basis of its technologies. In
addition, other factors that could cause actual results to differ
materially are discussed in the Company's filings with
OTCMarkets.com. The Company undertakes no obligation to publicly
release the results of any revisions to these forward looking
statements that may be made to reflect the events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events.
Contact: Institute of Biomedical Research Ljubljanska bb 81000
Podgorica, Montenegro Dr. Drasko Pekovic CEO Email:
info@InstituteBMR.com www.institutebmr.com
Grafico Azioni Institute of Biomedical ... (PK) (USOTC:MRES)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Institute of Biomedical ... (PK) (USOTC:MRES)
Storico
Da Mar 2024 a Mar 2025
